-
Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services
•
US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian market, has announced a strategic partnership agreement between its recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd. and Sinopharm Group Hubei Co., Ltd., a subsidiary of China’s Sinopharm Group Co., Ltd (HKG: 1099). The financial details…
-
BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China
•
German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099), granting the latter the rights to promote Boehringer Ingelheim’s Sifrol (pramipexole) and Pradaxa (dabigatran) in China effective from January 1, 2025. Boehringer Ingelheim will retain ownership and manufacturing responsibilities for both…
-
Sinopharm Holding Appoints New Chairman and President Following Leadership Changes
•
Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of its board of directors for the appointment of Zhao Bingxiang as the new chairman and Lian Wanyong as the president. This comes as former chairman Yu Qingming and president Liu Yong have stepped down from…
-
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
•
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry Co., Ltd, has made a notable debut by initiating an initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This marks the first pharmaceutical company to go public on this platform…
-
Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines
•
BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical Co., Ltd and Chengdu Institute of Biological Products Co., Ltd., part of Sinopharm, are on the path to priority review for their respective medical innovations. Ruidio’s Technetium [99mTc] hydrazine nicotinamide polyethylene glycol bicyclic RGD peptide…
-
Tonghua Dongbao Pharmaceuticals Partners with Sinopharm for Supply Chain and Market Expansion
•
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a strategic partnership with Sinopharm Group Co., Ltd, another Chinese firm. The collaboration encompasses various aspects including distribution channels, logistics delivery, bidding services, and market access. Financial details of the agreement were not disclosed. Sinopharm, leveraging its strengths…
-
Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations
•
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation (Sinopharm), has been dismissed from his role as a delegate to the 14th National People’s Congress due to suspicions of serious disciplinary and legal violations, as determined by the Standing Committee of the National People’s…
-
Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services
•
China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s Fresenius Kabi, enhancing collaboration across various sectors including drug sales, warehousing and distribution, as well as big health, medical care, and wellness. Financial details of the agreement were not disclosed. This partnership marks a continuation…
-
Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal
•
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing…
-
Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment
•
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG: 1099), have jointly introduced the first value-based payment (VBP) plan for lymphoma associated with Fosun Kite’s chimeric antigen receptor (CAR) T cell therapy, Yescarta (axicabtagene ciloleucel). Under this innovative plan, eligible patients who do not…
-
Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence
•
Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with Sinopharm Group Heilongjiang Co., Ltd., a major player in China’s pharmaceutical distribution sector. This collaboration is aimed at expanding Youcare’s market reach and resource pool, leveraging Sinopharm’s (HKG: 1099) extensive distribution channels and resource advantages.…
-
AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group Co., Ltd, (HKG: 1099) a leading Chinese pharmaceutical company, to improve access to novel drugs and explore standardized patient management practices in China. Expanding Access and Patient SupportThe collaboration will utilize Sinopharm’s extensive SPS+ professional…
-
Chinese Pharma Consortium Eyes Poland’s Neuca in Strategic European Market Acquisition
•
A consortium of China-based pharmaceutical companies, potentially including the state-owned giant Sinopharm (HKG: 1099), is reportedly considering the acquisition of Poland-based drug wholesaler Neuca. According to sources, the potential sale was discussed during a recent consultation between Neuca and Poland’s Competition and Consumer Office UOKIK. However, no specifics regarding the…
